Page 31 - நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nanoform Interim Report January – March (Q1) 2021 Nanoform Company Announcement Nanoform Interim Report January – March (Q1) 2021 Strong momentum continues: three new non-GMP lines commissioned, four new clients signed, and six new customer PoC projects commenced. In addition, positive results from first clinical study announced, two near-term business targets achieved (“First Biologics PoC in 2021” and “at least three new non-GMP lines in 2021”), next generation STARMAP ® launched, EUR 40 million successfully raised and commercial teams in the US and the UK further strengthened. 1-3/2021 key financials - Revenue EUR 278 thousand, growth + 85%, stemming from 14 different customer projects (EUR 150 thousand, 6 customer projects in 1-3/2020). - The gross profit and gross margin improved to EUR 243 thousand and 88%, respectively (EUR 103 thousand, 68%).

Eteläuomen läiSan diegoUnited statesUnited kingdomCelanese vitaldoseChris worralMiguel caladoBiologics poVp business developmentFinnish financial supervisory authorityEuropean biotech companyNacuity pharmaceuticalsFinland branchDanske bankCoast us biotech companyCelanese corporation